IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4.
IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4.
复制标题
IL-7 诱导人淋巴因子激活的杀伤细胞活性并受 IL-4 调节。
DOI：
10.4049/jimmunol.146.1.150
复制
发表时间：
1991
影响因子：
4.4
通讯作者：
M. T. Lotze
中科院分区：
文献类型：
--
作者：
H. Stötter;Mary C. Custer;Ellen S. Bolton;L. Guédez;M. T. Lotze
IL-2诱导淋巴因子激活杀手（LAK）活性已被描述为对新鲜和培养肿瘤具有广泛的细胞溶解活性。在缺乏IL-2的情况下，il -7也能在人细胞中诱导LAK活性。这种活性对IL-7来说是独特的，因为它不被其他细胞因子包括IL-1、IL-4、IL-6和tnf - α共享。IL-7还诱导表面标志物CD25 （Tac， IL-2R α链）、CD54 （ICAM-1）、Mic β 1 （IL-2R β链）和CD69（早期T细胞活化Ag）的重新表达或增加表达。il -7诱导的LAK活性不依赖于IL-2的分泌，因为它不会被IL-2抗血清消除。在il -2诱导的LAK细胞中，响应IL-7刺激的LAK前体在空细胞部分中富集。tgf - β和IL-4干扰IL-7产生LAK活性。抗il -4抗血清增强IL-7诱导的LAK活性，增强IL-7诱导的表面标记物表达。这可能是IL-7刺激诱导IL-4活性的间接证据。我们的结果描述了IL-7对成熟淋巴样细胞的激活作用。这和先前描述的IL-7在淋巴造血中的作用使其成为一种具有潜在治疗价值的细胞因子，可用于治疗免疫缺陷状态，并可能用于癌症的免疫治疗。
Induction of lymphokine-activated killer (LAK) activity by IL-2 has been described and characterized as broadly cytolytic activity against both fresh and cultured tumors. rIL-7 in the absence of IL-2 also induces LAK activity in human cells. This activity is unique for IL-7, because it is not shared by other cytokines including IL-1, IL-4, IL-6, and TNF-alpha. IL-7 also induces either de novo or increased expression of the surface markers CD25 (Tac, IL-2R alpha-chain), CD54 (ICAM-1), Mic beta 1 (IL-2R beta-chain) and CD69 (early T cell activation Ag). IL-7-induced LAK activity is independent of IL-2 secretion, because it is not abrogated by IL-2 antisera. The LAK precursor responding to IL-7 stimulation is enriched in the null cell fraction as has been demonstrated for IL-2-induced LAK cells. TGF-beta and IL-4 interfere with generation of LAK activity by IL-7. Anti-IL-4 antiserum enhances IL-7-induced LAK activity and augments induction of surface marker expression by IL-7. This may be indirect evidence that IL-7 stimulation leads to induction of IL-4 activity. Our results describe the activation of mature lymphoid cells by IL-7. This and the previously described role of IL-7 in lymphohemopoiesis makes it a cytokine of potential therapeutic value for treatment of immunodeficiency states and possibly the immunotherapy of cancer.